Been looking at some healthcare plays lately and stumbled on something worth discussing. Labcorp Holdings, ticker LH, is this major diagnostics company out of North Carolina that's been around handling clinical lab services and drug development support. They actually acquired Covance back in 2015, which expanded their whole drug development game significantly.

Here's what caught my attention: LH is sitting at a #3 Hold rating on the Zacks scale, but the VGM score is an A, which is pretty solid. More importantly for value hunters, the Value Style Score is a B thanks to some genuinely attractive valuation metrics. We're talking a forward P/E of 15.64, which isn't crazy expensive in the healthcare space.

The earnings momentum is interesting too. Four analysts bumped up their fiscal 2026 estimates in the last two months, and the consensus estimate climbed $0.04 to $17.65 per share. LH also has this consistent pattern of beating expectations - averaging a 3.1% earnings surprise, which shows management knows how to execute.

What makes this relevant right now is that combination of reasonable valuation plus actual earnings revisions moving in the right direction. You see a lot of stocks that look cheap but have deteriorating outlooks, or ones with good momentum but stretched valuations. LH seems to have both the value angle and positive estimate revisions supporting it.

The thing about LH is it's exactly the kind of stock that makes sense for a watchlist if you're looking at defensive healthcare exposure with actual growth catalysts. Not saying it's a slam dunk buy, but it's definitely one to keep on your radar if you're building a balanced portfolio. Healthcare diagnostics isn't the flashiest sector, but it's stable and LH's fundamentals are pointing in the right direction.